✦ LIBER ✦

The Distribution of Viral Blips Observed in HIV-1 Infected Patients Treated with Combination Antiretroviral Therapy

✍ Scribed by Jerome K. Percus; Ora E. Percus; Martin Markowitz; David D. Ho; Michele Di Mascio; Alan S. Perelson

Publisher: Springer
Year: 2003
Tongue: English
Weight: 136 KB
Volume: 65
Category: Article
ISSN: 1522-9602
DOI: 10.1016/s0092-8240(02)00095-2

No coin nor oath required. For personal study only.

✦ Synopsis

Human immunodeficiency virus type 1 (HIV-1) infected patients treated with combination antiretroviral therapy frequently have the level of HIV-1 RNA detectable in plasma driven below the lower limit of detection of current assays, 50 copies ml(-1). Patients may continue to exhibit viral loads (VLs) below the assay limit for years, yet on some occasions the VL may be above the limit of detection. Whether these 'blips' in VL are simply assay errors or are indicative of intermittent episodes of increased viral replication is of great clinical concern. By analyzing the occurrence of viral blips in 123 treated HIV-infected patients, we show that patients do not share a common probability distribution of blip amplitude and thus reject the hypothesis that blips are solely due to assay variation.

📜 SIMILAR VOLUMES

Deletions in env gene of HIV-1 in AIDS p

Deletions in env gene of HIV-1 in AIDS patients treated with highly active antiretroviral therapy (HAART)

✍ Shreesh Saurya; Zelman Lichtenstein; Abraham Karpas 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 141 KB

## Abstract Many AIDS patients retain high CD4+ T‐cell counts despite a significant increase in PCR viral load after varied periods of treatment on drug combination with Highly Active Antiretroviral Therapy (HAART). In order to investigate this contradictory phenomenon, we assayed for infectious HI

Failure of stavudine-lamivudine combinat

Failure of stavudine-lamivudine combination therapy in antiretroviral-naive patients with AZT-Like HIV-1 resistance mutations

✍ Loredana Sarmati; Emanuele Nicastri; Saverio Giuseppe Parisi; Gabriella D'Ettorr 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 96 KB

## Abstract To analyze the clinical relevance of AZT resistance mutations in AZT‐naive patients, 56 HIV‐1 seropositive patients treated for 18 months with stavudine/lamivudine (27 patients) or AZT/lamivudine (29 patients) were studied. AZT‐like resistance mutations were found in 13 out of 29 (44%)

Saquinavir delays the emergence of zidov

Saquinavir delays the emergence of zidovudine resistance in HIV-1 seropositive patients treated with combination therapy

✍ Andreoni, M.; Sarmati, L.; Nicastri, E.; Ventura, L.; Ercoli, L.; Parisi, S. G.; 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 102 KB 👁 2 views

During a randomized double-blind study to assess the antiviral activity of saquinavir (SQV) alone or in combination with zidovudine (ZDV), the emergence of phenotypic resistance was evaluated in 44 patients treated with SQV (13 subjects), ZDV (14 subjects), and SQV plus ZDV (17 subjects). A signific

Effects of potent antiretroviral therapy

Effects of potent antiretroviral therapy on the immune activation marker soluble CD27 in patients infected with HIV-1 subtypes A–D

✍ Ann Atlas; Tran Thi Thanh Ha; Anna Lindström; Anna Nilsson; Annette Alaeus; Fran 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 155 KB 👁 1 views

## Abstract HIV‐1 genetic subtypes might have a different impact on disease progression and response to antiretroviral therapy (ART). Few data are available on the immune activation profile in patients with different HIV‐1 subtypes. We have tested by ELISA the plasma levels of an immune activation

No pol mutation is associated independen

No pol mutation is associated independently with the lack of immune recovery in patients infected with HIV and failing antiretroviral therapy

✍ Nicola Gianotti; Laura Galli; Maurizio Zazzi; Valeria Ghisetti; Stefano Bonora; 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 233 KB 👁 2 views

## Abstract An investigation was undertaken to determine whether specific __pol__ mutations hinder long‐term immune recovery regardless of virological response. In total, 826 patients with >50 HIV RNA copies/ml, who underwent genotypic resistance testing between 1 January 2000 and 31 December 2003

Appearance of an inhibitor to factor VII

Appearance of an inhibitor to factor VIII in a hemophilia A patient with HIV infection treated with combination anti-retroviral therapy

✍ Bleak, Shirley; Rodgers, George M. 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 137 KB 👁 2 views